GOT1 Gene

📖 Wiki Page

gene1853 wordssynced 2026-04-02

GOT1 Gene

...

GOT1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">got1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GOT1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glutamic-Oxaloacetic Transaminase 1</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>AST1, cAST, AAT1, Aspartate Aminotransferase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>10q24.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2805</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000163283</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P17174</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>138150</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Enzyme; Aminotransferase</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's disease, Parkinson's disease, metabolic disorders</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Cytosol</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>GOT1</td>
</tr>
<tr>
<td class="label">Isoform length</td>
<td>413 aa</td>
</tr>
<tr>
<td class="label">Tissue distribution</td>
<td>Broad</td>
</tr>
<tr>
<td class="label">pI</td>
<td>5.4</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Cerebral cortex](/brain-regions/cortex)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">[Cerebellum](/brain-regions/cerebellum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Basal ganglia](/brain-regions/basal-ganglia)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Hassen et al. 2021</td>
<td>Metabolic dysfunction in AD brain</td>
</tr>
<tr>
<td class="label">Cunnane et al. 2020</td>
<td>Brain energy metabolism in AD</td>
</tr>
<tr>
<td class="label">Mehrabi et al. 2022</td>
<td>Astrocyte metabolic dysfunction</td>
</tr>
<tr>
<td class="label">Gandhi et al. 2020</td>
<td>Metabolic alterations in PD</td>
</tr>
<tr>
<td class="label">Kumar et al. 2023</td>
<td>Astrocyte-neuron coupling</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GOT2</td>
<td>Isozyme partner</td>
</tr>
<tr>
<td class="label">Glutamine synthetase</td>
<td>Enzyme coupling</td>
</tr>
<tr>
<td class="label">EAAT1/2</td>
<td>Transport coupling</td>
</tr>
<tr>
<td class="label">MDH1/2</td>
<td>Pathway coupling</td>
</tr>
<tr>
<td class="label">AGC1/2 (citrin)</td>
<td>Transporter</td>
</tr>
</table>

GOT1 (Glutamic-Oxaloacetic Transaminase 1), also known as Aspartate Aminotransferase 1 (AST1), cAST (cytosolic aspartate aminotransferase), or AAT1, encodes a crucial metabolic enzyme that catalyzes the reversible transamination between aspartate and α-ketoglutarate, producing glutamate and oxaloacetate. Located on chromosome 10q24.3, GOT1 plays essential roles in amino acid metabolism, the malate-aspartate shuttle, and neuronal energy metabolism. The enzyme is critical for maintaining glutamate and aspartate homeostasis in the brain and has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and various metabolic and neurodegenerative conditions.

Overview

Gene Structure

The GOT1 gene spans approximately 14 kb and consists of 11 exons encoding a 413-amino acid protein. The gene is widely expressed with highest levels in heart, liver, and brain. Alternative splicing generates multiple mRNA variants with tissue-specific expression patterns.

Protein Structure

GOT1 is a homodimeric enzyme:

Dimeric Structure

Subunit size — 413 amino acids per monomer (~45 kDa)
Quaternary structure — Active as homodimer (90 kDa)
Pyridoxal phosphate — Contains vitamin B6 cofactor at Lys258

Active Site

PLP binding — Pyridoxal 5'-phosphate forms Schiff base with Lys258
Substrate binding — Distinct sites for aspartate and α-ketoglutarate
Catalytic mechanism — Ping-pong bi-bi transamination

Isoenzyme Comparison

Function

Enzymatic Activity

GOT1 catalyzes the reversible transamination reaction:

L-Aspartate + α-Ketoglutarate ↔ Oxaloacetate + L-Glutamate

This reaction is central to multiple metabolic pathways:

Amino acid metabolism — Interconversion of aspartate and glutamate

Gluconeogenesis — Oxaloacetate is a key gluconeogenic intermediate

Urea cycle — Aspartate donates nitrogen for urea synthesis

Malate-aspartate shuttle — Transfers reducing equivalents across mitochondrial membrane

Malate-Apartate Shuttle

The malate-aspartate shuttle is the primary mechanism for transferring reducing equivalents (NADH) from cytosol to mitochondria in the brain:

Cytosolic GOT1 converts oxaloacetate + glutamate → aspartate + α-ketoglutarate

Aspartate is transported into mitochondria via the aspartate-glutamate carrier (AGC)

Mitochondrial GOT2 converts aspartate + α-ketoglutarate → oxaloacetate + glutamate

Malate dehydrogenase converts oxaloacetate + NADH → malate + NAD⁺

Malate enters mitochondria via malate-α-ketoglutarate carrier

Mitochondrial malate is converted back to oxaloacetate, generating NADH for oxidative phosphorylation

This shuttle is particularly important in neurons, which rely heavily on oxidative phosphorylation for energy. Unlike glycolysis, oxidative phosphorylation requires the malate-aspartate shuttle to transport electrons into the mitochondria.

Neurotransmitter Recycling

GOT1 is essential for glutamate-glutamine cycle:

Glutamate uptake — Astrocytes take up synaptic glutamate
Glutamine formation — Glutamate converted to glutamine by glutamine synthetase
Glutamine release — Released to neurons
GOT1 regeneration — Neuronal GOT1 converts glutamine back to glutamate

Other Metabolic Functions

TCA cycle anaplerosis — Provides oxaloacetate for citrate synthesis
Amino acid biosynthesis — Supports protein synthesis
Gluconeogenesis — Contributes to glucose generation in liver/kidney

Brain Expression

GOT1 is expressed throughout the brain with high activity in metabolically active regions:

Within the brain, GOT1 is expressed in both neurons and astrocytes:

Neuronal GOT1 — Primarily cytosolic, supports neurotransmitter synthesis
Astrocytic GOT1 — Critical for glutamate recycling and metabolic coupling

Cellular Localization

Cytosolic localization — Predominantly in cytosol
Mitochondrial association — Partial mitochondrial localization in some cells
Synaptic terminals — Present in presynaptic terminals for neurotransmitter recycling

Regulation

GOT1 activity is tightly regulated:

Transcriptional Regulation

Hormonal control — Glucocorticoids increase GOT1 expression
Nutritional state — Fasting alters hepatic GOT1
Developmental expression — High in developing brain

Allosteric Regulation

Product inhibition — Glutamate and oxaloacetate inhibit activity
Substrate activation — Aspartate and α-ketoglutarate activate
PLP availability — Requires pyridoxal phosphate

Post-translational Modifications

Phosphorylation — Some regulatory serine/threonine sites
Acetylation — Lysine acetylation affects activity
Proteolytic cleavage — Generated in certain stress conditions

Disease Associations

Alzheimer's Disease

GOT1 alterations have been extensively documented in [Alzheimer's disease](/diseases/alzheimers-disease). Multiple studies have shown that GOT activity is significantly reduced in AD brain tissue, with reported decreases of 30-50% compared to age-matched controls[@hassen2021]. This reduction is particularly pronounced in the hippocampus and cerebral cortex, regions most affected by AD pathology[@cunnane2020].

The metabolic dysfunction in AD involves several interconnected mechanisms that converge on GOT1 function:

Reduced GOT activity — 30-50% reduction in AD brain tissue[@a1988]
Altered aspartate-glutamate metabolism — Affects neurotransmitter pools and excitability
Impaired malate-aspartate shuttle — Contributes to mitochondrial dysfunction[@mehrabi2022]
Energy metabolism deficits — ATP production impaired in AD neurons due to reduced NADH shuttling
Excitotoxicity — Glutamate dysregulation contributes to neuronal death through NMDA receptor overactivation
Tau pathology interactions — Metabolic dysfunction exacerbates tau-induced damage

The malate-aspartate shuttle is particularly vulnerable in AD because neurons rely almost exclusively on oxidative phosphorylation, unlike astrocytes which can switch to glycolysis[@pellerin2008]. When GOT1 activity is reduced, the shuttle cannot efficiently transfer NADH from cytosol to mitochondria, leading to a critical energy deficit that compounds the already-impaired mitochondrial function in AD[@cunnane2020].

Parkinson's Disease

GOT1 is relevant to [Parkinson's disease](/diseases/parkinsons-disease) through its role in dopaminergic neuron metabolism and mitochondrial function[@gandhi2020]. The substantia nigra pars compacta, which degenerates in PD, has particularly high metabolic demands that make it vulnerable to GOT1 dysfunction:

Altered transaminase activities — Reduced in substantia nigra and striatum[@jager2000]
Mitochondrial dysfunction — Impaired NADH shuttle function compounds complex I deficiency
Excitotoxicity — Glutamate metabolism alterations may contribute to dopaminergic neuron death
Energy crisis — Complex I deficiency affects malate-aspartate shuttle efficiency

Dopaminergic neurons have uniquely high energy requirements due to their pacemaking activity, which continuously demands ATP for ionic gradient maintenance. The GOT1-mediated malate-aspartate shuttle is essential for meeting these demands, and any impairment can lead to neuronal dysfunction and death[@gandhi2020].

Amyotrophic Lateral Sclerosis

Motor neuron metabolism — GOT1 alterations in spinal cord
Excitotoxic mechanisms — Glutamate homeostasis disrupted
Astrocyte dysfunction — Impaired metabolic coupling

Metabolic Disorders

Non-alcoholic fatty liver disease — GOT1 elevated as marker
Cardiovascular disease — Metabolic syndrome affects brain GOT1
Diabetes — Altered glycemic control affects neuronal metabolism

Research and Clinical Evidence

Human Studies

Post-mortem studies have consistently shown GOT1 alterations in neurodegenerative diseases:

Biomarker Studies

Serum and CSF GOT levels show promise as biomarkers for neurodegenerative disease progression[@pal2016]. Elevated serum GOT1 is associated with:

Disease severity in AD and PD
Cognitive decline trajectory
Motor symptom progression in PD

Therapeutic Approaches

Current research is exploring several strategies targeting GOT1 and malate-aspartate shuttle function[@daniele2014]:

Metabolic enhancers — Compounds that boost shuttle activity

Cofactor supplementation — Alpha-ketoglutarate and pyridoxal phosphate

Astrocyte-targeted therapies — Restore metabolic coupling

Mitochondrial protectants — Preserve shuttle function

Molecular Mechanisms

Energy Metabolism

GOT1 supports neuronal energy through:

NADH transport — Shuttles electrons into mitochondria

ATP production — Supports oxidative phosphorylation

Metabolic flexibility — Enables alternative substrate utilization

Anaplerosis — Maintains TCA cycle intermediates

Neurotransmitter Cycling

The glutamate-glutamine cycle depends on GOT1:

Synaptic glutamate release — Vesicular release during neurotransmission

Astrocyte uptake — EAAT1/EAAT2 transport glutamate

GOT1 conversion — Glutamate → glutamine via GS

Neuronal uptake — Glutamine transported to neurons

GOT1 regeneration — Glutamine → glutamate in neurons

Oxidative Stress

GOT1 affects cellular redox status:

NAD⁺/NADH ratio — Shuttle activity maintains redox balance
Antioxidant support — Supports glutathione synthesis
Mitochondrial function — Electron transport chain support

Therapeutic Implications

GOT1 is a potential therapeutic target:

Metabolic Modulation

Enhancing malate-aspartate shuttle — Improve neuronal energy
Boosting astrocyte-neuron metabolic coupling — Restore metabolic support
Protecting against oxidative stress — NAD⁺/NADH ratio maintenance

Biomarker Potential

Serum GOT levels — Biomarker for neurodegenerative disease progression
CSF GOT activity — Diagnostic marker for AD and PD
GOT1 polymorphisms — Genetic risk modifiers

Drug Development

Small molecule activators — Enhance GOT1 activity
Modulators of malate-aspartate shuttle — Target metabolic coupling
Cofactor supplementation — Alpha-ketoglutarate as neuroprotective strategy

Interaction Network

External Links

[NCBI Gene: GOT1](https://www.ncbi.nlm.nih.gov/gene/2805)
[UniProt: GOT1](https://www.uniprot.org/uniprot/P17174)
[OMIM: 138150](https://omim.org/entry/138150)
[Ensembl: GOT1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163283)
[Allen Brain Atlas](https://human.brain-map.org/)

References

[Reich E, Glutamate-oxaloacetate transaminase (GOT) (1973)](https://pubmed.ncbi.nlm.nih.gov/4557890/)

[Sak K et al, Aspartate aminotransferase isoenzymes in mammalian tissues (2019)](https://pubmed.ncbi.nlm.nih.gov/31254289/)

[Bkelser AH et al, The malate-aspartate shuttle in brain mitochondria (1982)](https://pubmed.ncbi.nlm.nih.gov/6896357/)

[Belanger M et al, Brain energy metabolism: roles of astrocytes and neurons (2008)](https://pubmed.ncbi.nlm.nih.gov/18482676/)

[Pellerin L et al, Astrocyte-neuron metabolic coupling (2008)](https://pubmed.ncbi.nlm.nih.gov/19059904/)

[Schousboe A et al, Amino acid neurotransmitters: from extracellular space to metabolism (2001)](https://pubmed.ncbi.nlm.nih.gov/11744852/)

[A et al, Alterations of transaminases in Alzheimer's disease brain (1988)](https://pubmed.ncbi.nlm.nih.gov/3359705/)

[Jager W et al, Metabolic alterations in Parkinson's disease brain (2000)](https://pubmed.ncbi.nlm.nih.gov/11001059/)

[Kimelberg HK, Glutamate uptake and excitotoxicity (2009)](https://pubmed.ncbi.nlm.nih.gov/19686801/)

[Daniele S et al, Metabolic modulation in neurodegenerative diseases (2014)](https://pubmed.ncbi.nlm.nih.gov/24929925/)

[Pal R et al, Serum transaminases as biomarkers in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27871638/)

[Hassen G et al, Metabolic dysfunction in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34588934/)

[Mehrabi S et al, Astrocyte metabolic dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35633412/)

[Gandhi S et al, Metabolic alterations in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32804087/)

[Cunnane SC et al, Brain energy metabolism in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31830586/)

[Kumar A et al, Targeting astrocyte-neuron metabolic coupling (2023)](https://pubmed.ncbi.nlm.nih.gov/37213456/)

Pathway Diagram

The following diagram shows the key molecular relationships involving got1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving GOT1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

GOT1 Gene

GOT1 Gene

GOT1 Gene

Overview

Gene Structure

Protein Structure

Dimeric Structure

Active Site

Isoenzyme Comparison

Function

Enzymatic Activity

Malate-Apartate Shuttle

Neurotransmitter Recycling

Other Metabolic Functions

Brain Expression

Cellular Localization

Regulation

Transcriptional Regulation

Allosteric Regulation

Post-translational Modifications

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Metabolic Disorders

Research and Clinical Evidence

Human Studies

Biomarker Studies

Therapeutic Approaches

Molecular Mechanisms

Energy Metabolism

Neurotransmitter Cycling

Oxidative Stress

Therapeutic Implications

Metabolic Modulation

Biomarker Potential

Drug Development

Interaction Network

See Also

External Links

References

Pathway Diagram

Pathway Diagram